Prevention and treatment of systemic glucocorticoid side effects. - Wikidata - awgldk - TriplyDB

Prevention and treatment of systemic glucocorticoid side effects.

Prevention and treatment of systemic glucocorticoid side effects.

http://www.wikidata.org/entity/Q33857775

about

Honaucins A-C, potent inhibitors of inflammation and bacterial quorum sensing: synthetic derivatives and structure-activity relationships Management issues with exogenous steroid therapy Mucous membrane pemphigoid Pharmacological Management of Allergic Rhinitis in the Elderly Decrystallization of Crystals Using Gold "Nano-Bullets" and the Metal-Assisted and Microwave-Accelerated Decrystallization Technique Diet and dermatology: the role of dietary intervention in skin disease Glucocorticoids suppress selected components of the senescence-associated secretory phenotype.A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy Identifying chinese herbal medicine network for eczema: implications from a nationwide prescription database.PLAG (1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol) Modulates Eosinophil Chemotaxis by Regulating CCL26 Expression from Epithelial Cells.The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia Characteristics of traditional Chinese medicine users and prescription analysis for pediatric atopic dermatitis: a population-based study.Increased maternal nighttime cortisol concentrations in late gestation alter glucose and insulin in the neonatal lamb.A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.Forkhead box A3 mediates glucocorticoid receptor function in adipose tissue.A Single Dose of Prednisolone as a Modulator of Undercarboxylated Osteocalcin and Insulin Sensitivity Post-Exercise in Healthy Young Men: A Study Protocol.Curcumin suppresses NTHi-induced CXCL5 expression via inhibition of positive IKKβ pathway and up-regulation of negative MKP-1 pathway.A current update on osteonecrosis of the jaw and bisphosphonates.The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia.Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus.Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction.Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.Mustard Gas Inhalation Injury: Therapeutic Strategy.Nephrotic syndrome; is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis?IP6K1 Reduces Mesenchymal Stem/Stromal Cell Fitness and Potentiates High Fat Diet-Induced Skeletal Involution.Emerging corticosteroid agonists for the treatment of asthma.An Overview of Organ-Specific Autoimmune Diseases Including Immunotherapy.High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.Complications of Guillain-Barré syndrome.Caerulomycin A suppresses the differentiation of naïve T cells and alleviates the symptoms of experimental autoimmune encephalomyelitis.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.Preoperative steroids for hearing preservation cochlear implantation: A review.Oral Steroid Usage for Otitis Media with Effusion, Eustachian Tube Dysfunction, and Tympanic Membrane Retraction.Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.Therapeutic Dilemma of Refractory Erythema Nodosum Leprosum.Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis.Charge based intra-cartilage delivery of single dose dexamethasone using Avidin nano-carriers suppresses cytokine-induced catabolism long term Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.Dexamethasone, tetrahydrobiopterin and uncoupling of endothelial nitric oxide synthase.

P2860

Q21994482-7578299B-04CD-40DC-8D09-FCC415FF1465 Q24564449-760C5D78-0A2E-4B8A-9A81-AF309E9D6DE1 Q27691456-4D0A6C13-0849-4728-B086-EC2C10A433BB Q30240237-B489459C-A599-4706-B4F6-186FA49CE7EA Q33615722-B2A30543-FCE5-45B2-8906-3E6A2EE1F411 Q33931312-EF07F527-BB85-4DD9-A466-75A43397ACE1 Q34190186-AAC7B6BF-1B9B-4DCE-A878-FDF02C5214B8 Q34364143-81E21403-31F1-49B2-BA32-E291CF7CDCEE Q35061535-D6789940-340F-48C9-8904-46C92EEA99D4 Q35968661-C16CB1A6-0FB7-410A-BE81-111A021EBD08 Q35997653-409CEAC6-181E-41AC-A097-7689AEC19D9B Q36045269-6B6752AF-4666-4C9D-B9F0-B9764F5FFB81 Q36144576-80F19542-FAB0-43FA-8E42-2474CCD5D714 Q36371799-AE080FB9-2096-4913-AA84-2125E0B07055 Q36742933-8CDE91E5-E2FC-4AA4-98A0-55833DF446DC Q37017874-2EDEF015-5E4E-40D5-9B21-12C95F366546 Q37188938-589416B8-D727-4A02-9F28-F2C9011A02E2 Q37992647-3644BF9A-02A4-4384-92E1-3FE1B16A3748 Q38012165-40F665BB-C032-4EDF-A36C-232AEA570059 Q38095599-24D7D6BF-63C9-4CC7-A65C-467EC7A68018 Q38180822-BEE247E2-5201-4ACF-B245-41C99243B70A Q38206050-E1840E12-6A3C-41E1-9DF8-4768B04F76C6 Q38209766-D6458121-106C-4116-9F22-EB95F4BECD56 Q38305277-A6F88F3D-20DF-4C8B-B1A9-4C4901D2EAEE Q38430822-A0108AAD-C505-4B4F-A949-C684BBA4F9F2 Q38537176-B4FE7911-D110-4D50-9E6E-F9A31CF3C3BA Q38635415-62D8E637-864B-4ABA-B424-8547070F100A Q38658597-0217530A-E8CB-4790-B9EC-3D16B1CB2C6F Q38661132-61045B35-6345-45A2-BB2F-76A25557F8B4 Q38661294-285AC173-8828-4BAF-B19D-A6B703E0E5B8 Q38679589-E3EA5B9E-B804-4D37-8585-BA8146474F2E Q38704139-8BDCEB44-1058-4D4E-8407-95AEA928152D Q38749399-C44331DA-62CF-4D97-B6E5-489622B7A776 Q39878907-B7EAD826-59F7-4BE6-8193-AE8BF93815E8 Q40047193-200A98A0-721C-4D6A-9227-638F974D923E Q40130330-F5C7A001-8F8A-4EEF-AA3B-59058CF4F157 Q41211501-AC61F220-D2F5-4B77-99F7-D7DC1136695A Q41525275-7A863AA5-2720-4DE5-9C94-86F828C062D6 Q41709276-80E7549E-A872-4340-8938-536F56993173 Q43220700-020A289D-4B60-4E5E-8C17-42574714BFAB

P2860

Prevention and treatment of systemic glucocorticoid side effects.

http://www.wikidata.org/entity/Q33857775

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Prevention and treatment of systemic glucocorticoid side effects.

@ast

Prevention and treatment of systemic glucocorticoid side effects.

@en

type

label

Prevention and treatment of systemic glucocorticoid side effects.

@ast

Prevention and treatment of systemic glucocorticoid side effects.

@en

prefLabel

Prevention and treatment of systemic glucocorticoid side effects.

@ast

Prevention and treatment of systemic glucocorticoid side effects.

@en

P1433

Q33857775-1C0C91A1-2312-4077-A421-2BCBB785D257

P1476

Q33857775-8D005E66-58CF-4EBD-A266-803A50CF053D

P2093

Q33857775-490BDAD4-47D3-4AB0-8CAD-C03CCC8E9019

Q33857775-C0DF41C4-1C9A-4BD8-A3CB-FE4D78F7EC48

P2860

Q33857775-064DDF82-6CD5-49AB-84F7-E497B4805245

Q33857775-0D3F2E55-A597-4C51-A59A-E0377F67DD2E

Q33857775-1187EEB6-D726-47D1-B060-890FE989829F

Q33857775-14142D52-EB87-4AC2-8747-F0E916CAAF7C

Q33857775-17701F87-84C7-4731-95EA-EB814F98B797

Q33857775-1CB45C7C-577D-4899-8269-64A656AA8082

Q33857775-1F40425D-BC0A-4041-B238-7D943C70D839

Q33857775-33BB6A51-193C-4FD4-A728-04C6E53121F4

Q33857775-3F95B659-2E6B-4D07-B667-F2D1E72A93D8

Q33857775-419B1E94-5346-4959-A1AE-CFD9065050A1

P304

Q33857775-12444B03-CFA7-4BEF-8199-6F77C1208DE8

P31

Q33857775-CBA3A47F-A182-4F01-BF6F-2D39DA3955AE

P356

Q33857775-32284DE5-231A-4556-B955-67C33DFCC99A

P433

Q33857775-625F4B30-ECBC-49BD-8CFE-F6D8F71A5F09

P478

Q33857775-1DFACB80-DC9A-4540-825C-E005BF0A3E52

P577

Q33857775-E4519E73-E990-4349-A8F0-75CCBD066909

P5875

Q33857775-3A4CF38A-546B-4F21-AA97-37907E7C6011

P698

Q33857775-20A2ABC4-722A-46C0-8848-F85034813690

P932

Q33857775-8640BE0D-5B6B-45AB-ADBA-C28BCAA03A4F

P356

J.1365-4632.2009.04322.X

P1433

International Journal of Dermatology

P1476

Prevention and treatment of systemic glucocorticoid side effects.

@en

P2093

Siamak Moghadam-Kia

http://www.w3.org/2001/XMLSchema#string

Victoria P Werth

http://www.w3.org/2001/XMLSchema#string

P2860

Risk factors for hydrocortisone myopathy in acute severe asthma

Blockade of glucocorticoid receptor binding and inhibition of dexamethasone-induced muscle atrophy in the rat by RU38486, a potent glucocorticoid antagonist

Sleep disorders. Steroids cause sleep disturbance

Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.

The effect on memory of chronic prednisone treatment in patients with systemic disease.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.

Neuromuscular sequelae of critical illness.

Glucocorticoids differentially regulate degradation of MyoD and Id1 by N-terminal ubiquitination to promote muscle protein catabolism

Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.

P304

239-248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-4632.2009.04322.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44595140

http://www.w3.org/2001/XMLSchema#string

P698

20465658

http://www.w3.org/2001/XMLSchema#string

P932

2872100

http://www.w3.org/2001/XMLSchema#string